Literature DB >> 29662120

An early history of T cell-mediated cytotoxicity.

Pierre Golstein1, Gillian M Griffiths2.   

Abstract

After 60 years of intense fundamental research into T cell-mediated cytotoxicity, we have gained a detailed knowledge of the cells involved, specific recognition mechanisms and post-recognition perforin-granzyme-based and FAS-based molecular mechanisms. What could not be anticipated at the outset was how discovery of the mechanisms regulating the activation and function of cytotoxic T cells would lead to new developments in cancer immunotherapy. Given the profound recent interest in therapeutic manipulation of cytotoxic T cell responses, it is an opportune time to look back on the early history of the field. This Timeline describes how the early findings occurred and eventually led to current therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29662120     DOI: 10.1038/s41577-018-0009-3

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  53 in total

1.  An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion.

Authors:  John D Klement; Amy V Paschall; Priscilla S Redd; Mohammed L Ibrahim; Chunwan Lu; Dafeng Yang; Esteban Celis; Scott I Abrams; Keiko Ozato; Kebin Liu
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

Review 2.  Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.

Authors:  Ning Zhu; Shanshan Weng; Juan Wang; Jiaqi Chen; Linzhen Yu; Xuefeng Fang; Ying Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-15       Impact factor: 4.553

3.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

4.  Loss of Fas Expression and Function Is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy.

Authors:  Wei Xiao; Mohammed L Ibrahim; Priscilla S Redd; John D Klement; Chunwan Lu; Dafeng Yang; Natasha M Savage; Kebin Liu
Journal:  Mol Cancer Res       Date:  2018-11-14       Impact factor: 5.852

Review 5.  Immune cell diversity contributes to the pathogenesis of myocarditis.

Authors:  Xiumeng Hua; Jiangping Song
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

6.  LRCH1 deficiency enhances LAT signalosome formation and CD8+ T cell responses against tumors and pathogens.

Authors:  Chang Liu; Xiaoyan Xu; Lei Han; Xiaopeng Wan; Lingming Zheng; Chunyang Li; Zhaohui Liao; Jun Xiao; Ruiyue Zhong; Xin Zheng; Qiong Wang; Zonghai Li; Hualan Chen; Bin Wei; Hongyan Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-29       Impact factor: 11.205

7.  SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.

Authors:  Chunwan Lu; John D Klement; Dafeng Yang; Thomas Albers; Iryna O Lebedyeva; Jennifer L Waller; Kebin Liu
Journal:  Cancer Lett       Date:  2020-02-12       Impact factor: 8.679

8.  Integrated analysis identifies S100A16 as a potential prognostic marker for pancreatic cancer.

Authors:  Tian Chen; De-Meng Xia; Chao Qian; Shan-Rong Liu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

9.  Stochastic Model of T Cell Repolarization during Target Elimination I.

Authors:  Ivan Hornak; Heiko Rieger
Journal:  Biophys J       Date:  2020-02-15       Impact factor: 4.033

10.  MS4A1 expression and function in T cells in the colorectal cancer tumor microenvironment.

Authors:  T William Mudd; Chunwan Lu; John D Klement; Kebin Liu
Journal:  Cell Immunol       Date:  2020-12-14       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.